ClinicalTrials.gg
RecruitingNCT04558450CARTESIANUpdated Nov 22, 2021

Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)

An interventional study of carotid-femoral pulse-wave velocity in Covid19, Arterial Stiffness and Endothelial Dysfunction, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2023, 3 years 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
17th of 59
360 · median 150
Started
2020
with 67 others
No phase
33 of 115
3 open now
Primary completion
2023-03
later than 1 of 10 live
Registered
51st of 115
by date

Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, this one is the 17th largest by planned enrollment of the 59 interventional ones that give a count, is one of 68 that started in 2020, is one of 33 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 51st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the presence of early vascular aging 6 months and 12 months after COVID-19 infection.

Read the detailed description

After being informed about the study and potential risks, all eligible patients giving written informed consent will undergo a comprehensive non-invasive assessment of vascular and cardiac function 6 months and 12 months after COVID-19 infection. Cardiovascular events and mortality will be collected 2, 5 and 10 years after inclusion

03

Conditions studied

  • Covid19
  • Arterial Stiffness
  • Endothelial Dysfunction
  • Diastolic Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18 years, both sexes;
  • written ;
  • affiliation to a social security regime;
  • a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group 1,2,3)
  • hospitalization in intensive care unit for COVID19 (for group 1)
  • hospitalization in a medicine unit for COVID19 (for group 2)
  • no hospitalization for COVID19 or hospitalization less than 24h (for group 3)
  • a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4)

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Inability to express consent of the study
  • Diseases carrying out a life -expectancy \<1 year according to clinical judgment
  • Pregnancy and breastfeeding
  • Foreseen inability to attend scheduled visits
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Other
    Group 1

    Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit

    Diagnostic Test: carotid-femoral pulse-wave velocity

  • Other
    Group 2

    Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit

    Diagnostic Test: carotid-femoral pulse-wave velocity

  • Other
    Group 3

    Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization

    Diagnostic Test: carotid-femoral pulse-wave velocity

  • Other
    Group 4

    4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative

    Diagnostic Test: carotid-femoral pulse-wave velocity

Interventions

  • Diagnostic testcarotid-femoral pulse-wave velocity

    early vascular aging tests

    Also known as: arterial distensibility, wave separation/intensity analysis, flow-mediated dilation, cardiac diastolic dysfunction, myocardial stiffness, central blood pressure

06

What researchers measure

Primary outcomes

  1. PWV

    carotid-femoral pulse wave velocity measured by application tonometry

    Time frame: 6 months after COVID19 infection

  2. PWV

    carotid-femoral pulse wave velocity measured by application tonometry

    Time frame: 12 months after COVID19 infection

  3. PWV change

    carotid-femoral pulse wave velocity measured by application tonometry

    Time frame: difference between PWV at 12 and 6 months after COVID19 infection

Secondary outcomes

  1. arterial distensibility

    carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound

    Time frame: 6 months after COVID19 infection

  2. arterial distensibility

    carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound

    Time frame: 12 months after COVID19 infection

  3. arterial distensibility change

    carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound

    Time frame: difference between arterial distensibility at 12 and 6 months after COVID19 infection

  4. brachial artery FMD

    brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis

    Time frame: 6 months after COVID19 infection

  5. brachial artery FMD

    brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis

    Time frame: 12 months after COVID19 infection

  6. brachial artery FMD change

    brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis

    Time frame: difference between FMD at 12 and 6 months after COVID19 infection

  7. central blood pressure

    central blood pressure obtained non-invasively by application tonometry and validated transfer function

    Time frame: 6 months after COVID19 infection

  8. central blood pressure

    central blood pressure obtained non-invasively by application tonometry and validated transfer function

    Time frame: 12 months after COVID19 infection

  9. central blood pressure (BP) change

    central blood pressure obtained non-invasively by application tonometry and validated transfer function

    Time frame: difference between central BP at 12 and 6 months after COVID19 infection

  10. wave separation/wave intensity analysis (WSA/WIA)

    peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk

    Time frame: 6 months after COVID19 infection

  11. wave separation/wave intensity analysis (WSA/WIA)

    peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk

    Time frame: 12 months after COVID19 infection

  12. WSA/WIA change

    peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk

    Time frame: difference between WSA/WIA at 12 and 6 months after COVID19 infection

  13. cardiac diastolic dysfunction

    E/e' at rest and after low-level exercise

    Time frame: 6 months after COVID19 infection

  14. cardiac diastolic dysfunction

    E/e' at rest and after low-level exercise

    Time frame: 12 months after COVID19 infection

  15. cardiac diastolic dysfunction change

    E/e' at rest and after low-level exercise

    Time frame: difference between cardiac diastolic dysfunction at 12 and 6 months after COVID19 infection

  16. myocardial stiffness

    cardioelastography by ultrafast ultrasound

    Time frame: 6 months after COVID19 infection

  17. myocardial stiffness

    cardioelastography by ultrafast ultrasound

    Time frame: 12 months after COVID19 infection

  18. myocardial stiffness change

    cardioelastography by ultrafast ultrasound

    Time frame: difference between myocardial stiffness at 12 and 6 months after COVID19 infection

  19. carotid femoral and hearth carotid change

    Mesure by laser doppler vibrometry

    Time frame: 6 months after COVID19 infection

Other outcomes

  1. total mortality

    individual data will be meta-analyzed with sister studies running in parallel worldwide

    Time frame: 2 years

  2. total mortality

    individual data will be meta-analyzed with sister studies running in parallel worldwide

    Time frame: 5 years

  3. total mortality

    individual data will be meta-analyzed with sister studies running in parallel worldwide

    Time frame: 10 years

  4. CV events

    fatal+non-fatal

    Time frame: 2 years

  5. CV events

    fatal+non-fatal

    Time frame: 5 years

  6. CV events

    fatal+non-fatal

    Time frame: 10 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared

Supporting information: Study protocol, Informed consent form

Time frame: One year after the last publication

Access criteria: Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and PI team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Mar 2023, 30 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 30 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 22, 2020
StartActual
Sep 21, 2020
Primary completionEst.
Mar 2023
CompletionEst.
Mar 2033
Last update
Nov 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04558450
Collaborators
The Association for Research into Arterial Structure and Physiology, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Sep 21, 2020
Primary completion
Mar 2023 (estimated)
Completion
Mar 2033 (estimated)
Last update
Nov 22, 2021

Study contacts

Rosa Maria BRUNO, MD
Contact
rosa-maria.bruno@inserm.fr
+33 1 53 98 79 67
Laura LE MAO, MSc
Contact
laura.le-mao@aphp.fr
+33 1 56 09 54 97
Pierre BOUTOUYRIE, MD PHD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion